Oruka Therapeutics (ORKA) Projected to Post Quarterly Earnings on Wednesday

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) is expected to announce its Q1 2026 results before the market opens on Wednesday, May 13th. Analysts expect the company to announce earnings of ($0.52) per share for the quarter. Investors can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 4:00 PM ET.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its quarterly earnings data on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, topping analysts' consensus estimates of ($0.61) by $0.16. On average, analysts expect Oruka Therapeutics to post $-2 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Oruka Therapeutics Price Performance

Shares of ORKA opened at $68.95 on Wednesday. The stock's 50-day moving average is $50.30 and its two-hundred day moving average is $37.30. The stock has a market cap of $3.46 billion, a PE ratio of -37.07 and a beta of -0.20. Oruka Therapeutics has a 12 month low of $8.91 and a 12 month high of $91.00.

Insider Transactions at Oruka Therapeutics

In other news, insider Joana Goncalves sold 7,000 shares of Oruka Therapeutics stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $66.12, for a total transaction of $462,840.00. Following the sale, the insider directly owned 33,377 shares of the company's stock, valued at approximately $2,206,887.24. The trade was a 17.34% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $41.30, for a total value of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 23,765 shares of company stock worth $1,089,745. Corporate insiders own 23.49% of the company's stock.

Institutional Trading of Oruka Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada increased its position in shares of Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock worth $34,000 after acquiring an additional 365 shares during the last quarter. Kennedy Capital Management LLC increased its position in shares of Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company's stock worth $1,476,000 after acquiring an additional 420 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company's stock worth $92,000 after acquiring an additional 788 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the fourth quarter worth about $37,000. Finally, PNC Financial Services Group Inc. purchased a new stake in shares of Oruka Therapeutics during the third quarter worth about $39,000. 56.44% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have commented on ORKA shares. UBS Group boosted their price objective on Oruka Therapeutics from $75.00 to $100.00 and gave the stock a "buy" rating in a research note on Tuesday, April 28th. Guggenheim set a $200.00 price objective on Oruka Therapeutics and gave the stock a "buy" rating in a research note on Monday, April 27th. Weiss Ratings restated a "sell (d-)" rating on shares of Oruka Therapeutics in a research note on Tuesday, April 21st. Leerink Partners set a $120.00 price objective on Oruka Therapeutics in a research note on Thursday, April 30th. Finally, Stifel Nicolaus boosted their price objective on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a "buy" rating in a research note on Friday, March 13th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Oruka Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $120.80.

About Oruka Therapeutics

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.